What Will Be Impact of Allowing Abortion Pill to be Mail-Ordered?
December
22
Earlier this month, as the debate over legal abortion in the U.S. intensified, the FDA removed a requirement that the pregnancy-ending drug mifepristone be dispensed only in clinics, medical offices and hospitals. That move will effectively open the door for “certified prescribers or pharmacies” in states that haven’t already banned the practice to dispense mifepristone by mail.
Experts tell AIS Health, however, that there are more questions than answers about how those loosened regulations will ultimately affect patient access to the controversial drug, as well as how industry players such as health plans and PBMs will be affected.
© 2022 MMIT
Meet Our Reporters
-
Angela Maas Managing Editor, RADAR on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and RADAR on Drug Benefits
View Leslie Small's Profile -
Lauren Flynn Kelly Managing Editor, RADAR on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Peter Johnson Reporter, Health Plan Weekly and RADAR on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and RADAR on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, RADAR on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and RADAR on Drug Benefits
View Jinghong Chen's Profile -
Jill Brown Kettler Executive Editor
View Jill Brown Kettler's Profile
